Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency
(2001) Kidney International — Vol. 60, n° 2, p. 741-747 (2001)
Files
236272.pdf
Restricted Access - Adobe PDF
- 200.17 KB
Details
- Authors
- Abstract
- Background: Novel erythropoiesis stimulating protein (NESP) is a glycoprotein with a threefold longer terminal half-life than recombinant human erythropoietin (rHuEPO) in humans. The aim of this study was to determine whether NESP is effective for the treatment of anemia at a reduced dosing frequency relative to rHuEPO in patients with chronic renal failure not yet on dialysis [chronic renal insufficiency (CRI)]. Methods: This was a multicenter, randomized, open-label study. A total of 166 rHuEPO-naive patients with CRI were randomized in a 3:1 ratio to receive NESP (0.45 microg/kg once weekly) or rHuEPO (50 U/kg twice weekly) administered subcutaneously for up to 24 weeks. Dose adjustments were made as necessary to achieve a hemoglobin response, defined as an increase > or =1.0 g/dL from baseline and a concentration > or = 11.0 g/dL. Results: During the 24-week treatment period, 93% (95% CI, 87 to 97%) of patients receiving NESP and 92% (95% CI, 78 to 98%) of patients receiving rHuEPO achieved a hemoglobin response. The median time to response was seven weeks (range of 3 to 25 weeks) in both groups. After correction of anemia, mean hemoglobin concentrations were maintained within the target range of 11.0 to 13.0 g/dL for the remainder of the 24-week treatment period. The safety profiles of NESP and rHuEPO were similar, and no antibodies were detected to either drug. Conclusions: These results demonstrate that NESP safely and effectively corrects and maintains hemoglobin concentrations at a reduced dosing frequency relative to rHuEPO in patients with CRI, providing a potential benefit to patients and health care providers.
- Affiliations
Citations
Locatelli, F., Olivares, J., Walker, R., Wilkie, M., Jenkins, B., Dewey, C., & Gray, S. J. (2001). Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney International, 60(2), 741-747. https://doi.org/10.1046/j.1523-1755.2001.060002741.x (Original work published 2001)